AstraZeneca PLC Director/PDMR Shareholding (5981S)
12 March 2019 - 11:00PM
UK Regulatory
TIDMAZN
RNS Number : 5981S
AstraZeneca PLC
12 March 2019
12 March 2019 12:00 GMT
TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL
RESPONSIBILITIES
AstraZeneca PLC (the Company) announces that, on 8 March 2019,
certain Persons Discharging Managerial Responsibilities of the
Company (PDMRs) were granted awards of the Company's ordinary
shares of $0.25 each (Ordinary Shares) under the terms of the
AstraZeneca Deferred Bonus Plan (AZDBP) and the AstraZeneca
Performance Share Plan (AZPSP), as detailed in the table below.
PDMR Ordinary Shares Ordinary Shares Award price per
granted under granted under Ordinary Share
the AZDBP the AZPSP
Pascal Soriot 9,849 102,475 GBP62.87
---------------- ---------------- ----------------
Marc Dunoyer 4,874 48,690 GBP62.87
---------------- ---------------- ----------------
The AZDBP award represents the portion of each PDMR's annual
bonus for 2018 that they are required to defer into shares. The
Ordinary Shares granted under the AZDBP are subject to a three-year
holding period and are due to vest on the third anniversary of
grant.
The AZPSP award is subject to a combination of performance
measures focused on scientific, commercial and financial
performance assessed over a three-year performance period (1
January 2019 to 31 December 2021). The Ordinary Shares granted
under the AZPSP are subject to a two-year holding period following
the performance period, and are due to vest on the fifth
anniversary of grant.
Details of the performance measures attached to the AZPSP award
can be found in the Directors' Remuneration Report within the
AstraZeneca Annual Report and Form 20-F Information 2018, which is
available on the Company's website at
www.astrazeneca.com/annualreport2018.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Pascal Soriot
---------------------------- -------------------------------------
2 Reason for the notification
-------------------------------------------------------------------
a) Position/status Chief Executive Officer
---------------------------- -------------------------------------
b) Initial notification Initial notification
/Amendment
---------------------------- -------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------
a) Name AstraZeneca PLC
---------------------------- -------------------------------------
b) LEI PY6ZZQWO2IZFZC3IOL08
---------------------------- -------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------
a) Description of the Ordinary Shares of US$0.25 each in
financial instrument, AstraZeneca PLC
type of instrument
Identification code GB0009895292
---------------------------- -------------------------------------
b) Nature of the transaction Grants of share awards under the
AstraZeneca Performance Share Plan
and the AstraZeneca Deferred Bonus
Plan
---------------------------- -------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
GBP62.87 112,324
----------
---------------------------- -------------------------------------
d) Aggregated information Not applicable - single transaction
- Aggregated volume
- Price
---------------------------- -------------------------------------
e) Date of the transaction 8 March 2019
---------------------------- -------------------------------------
f) Place of the transaction Outside a trading venue
---------------------------- -------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Marc Dunoyer
---------------------------- -------------------------------------
2 Reason for the notification
-------------------------------------------------------------------
a) Position/status Chief Financial Officer
---------------------------- -------------------------------------
b) Initial notification Initial notification
/Amendment
---------------------------- -------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------
a) Name AstraZeneca PLC
---------------------------- -------------------------------------
b) LEI PY6ZZQWO2IZFZC3IOL08
---------------------------- -------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------
a) Description of the Ordinary Shares of US$0.25 each in
financial instrument, AstraZeneca PLC
type of instrument
Identification code GB0009895292
---------------------------- -------------------------------------
b) Nature of the transaction Grants of share awards under the
AstraZeneca Performance Share Plan
and the AstraZeneca Deferred Bonus
Plan
---------------------------- -------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
GBP62.87 53,564
----------
---------------------------- -------------------------------------
d) Aggregated information Not applicable - single transaction
- Aggregated volume
- Price
---------------------------- -------------------------------------
e) Date of the transaction 8 March 2019
---------------------------- -------------------------------------
f) Place of the transaction Outside a trading venue
---------------------------- -------------------------------------
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company
that focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three therapy areas - Oncology, Cardiovascular, Renal &
Metabolism and Respiratory. AstraZeneca operates in over 100
countries and its innovative medicines are used by millions of
patients worldwide. For more information, please visit
www.astrazeneca.com and follow us on Twitter @AstraZeneca.
Media Relations
Gonzalo Viña UK/Global +44 203 749 5916
Rob Skelding UK/Global +44 203 749 5821
Matt Kent UK/Global +44 203 749 5906
Jennifer Hursit UK/Global +44 203 749 5762
Christina Malmberg Hägerstrand Sweden +46 8 552 53 106
Michele Meixell US +1 302 885 2677
Investor Relations
Thomas Kudsk Larsen +44 203 749 5712
Henry Wheeler Oncology +44 203 749 5797
Christer Gruvris BioPharma - Cardiovascular; Metabolism +44 203 749 5711
Nick Stone BioPharma - Respiratory; Renal +44 203 749 5716
Josie Afolabi Other +44 203 749 5631
Craig Marks Finance; Fixed Income +44 7881 615 764
Jennifer Kretzmann Retail Investors; Corporate Access +44 203 749 5824
US toll-free +1 866 381 72 77
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHUUARRKNAOAAR
(END) Dow Jones Newswires
March 12, 2019 08:00 ET (12:00 GMT)
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2024 to May 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From May 2023 to May 2024
